Grade: Pharmaceutical Grade

Factory Location: Quanzhou

Main Sales Markets: North America,Central/South America,Western Europe,Eastern Europe,Australasia,Asia,Middle East,Africa

Sample Provided: no

Payment Terms: L/C

Upatinib is an oral JAK1 inhibitor used to treat rheumatoid arthritis, psoriatic arthritis and other diseases. JAK kinases are a family of non-receptor tyrosine kinases with four known members: JAK1, JAK2, JAK3 and TYK1. The substrates of JAK are STAT, which are signal transducers and transcriptional activators. STAT dimerized after being phosphorylated by JAK, and then passed through the nuclear membrane into the nucleus to regulate the expression of related genes. This signaling pathway is called JAK-STAT pathway. Therefore, JAK plays an important role in the pathophysiological process of immune-mediated diseases, and can be used to treat some autoimmune diseases, such as atopic dermatitis and rheumatoid arthritis. Psoriasis, ulcerative colitis, etc